The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...
FRIDAY, Jan. 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain ...
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
CNBC’s Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the ...
Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration. The drugmaker said the twice-daily pill, Journavx, is the first such treatment to hit the market ...
Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way for the rollout of a product that has simultaneously sparked high hopes and ...